Trial · NCT02917928
The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health
NCT02917928, Phase 2, Unknown, Monash University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health. Trials, record NCT02917928. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02917928
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health
- NCT number
- NCT02917928
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Monash University
- Conditions
- Poor Glycemic Control, Cardiovascular Risk Factors, Cognitive Function 1, Social
- Interventions
- carnosine, Placebo
- First posted
- 2016-09-28
- Last updated
- 2022-06-28
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Oral Glucose Tolerance Test | baseline and 14 weeks | After a 10-12 h overnight fast, participants will ingest 75g of glucose over 2 mins. Blood samples will be drawn at 0, 30, 60, 90 and 120 min for plasma glucose and insulin concentrations. We will evaluate the area under the curve. |
| Secondary | Change in HbA1c | baseline and 14 weeks | Blood samples will be measured using High Performance Liquid Chromatography. |
| Secondary | Change in lipid profile | baseline and 14 weeks | Blood samples will be analysed using High Performance Liquid Chromatography |
| Secondary | Change in systolic and diastolic blood pressure | baseline and 14 weeks | Resting systolic and diastolic blood pressure and pulse rate will be measured using an automated oscillometric measurement system (Dinamap, USA) after a 30 minute rest. |
| Secondary | Change in arterial stiffness and central blood pressure | baseline and 14 weeks | Aortic (carotid-femoral) pulse wave velocity (aPWV) will be measured using the non-invasive Complior device (Alam Medical, French). |
| Secondary | Change in markers of endothelial dysfunction | baseline and 14 weeks | This is done using non-invasive peripheral arterial tomography (PAT; endothelium-dependent digital pulse amplitude testing (EndoPAT), Itamar Medical Ltd, Israel), which records continuous plethysmographic signals of the finger arterial pulse wave. Finger plethysmographic probes are placed on each index finger; and after a 5 min equilibration period, a blood pressure cuff on the non-dominant arm is inflated to 60 mmHg above systolic for 5 min and then deflated to induce reactive hyperaemia. Measurements of post-occlusion changes (reactive hyperaemia PAT: RH-PAT) are continued for 10 min. Results are normalised to the non-occluded arm, compensating for potential systemic changes (RH-PAT ratio). |
| Secondary | Change in heart rate variability | baseline and 14 weeks | The Zephyr Biomodule BH3 (Black Sensor, produced by Zephyr Technology) will be used to measure heart rate and heart rate variability for three consecutive days. |
| Secondary | Change in interleukins | baseline and 14 weeks | Interleukins will be measured by quantitative sandwich enzyme immunoassays (R \& D Systems Inc, USA). |
| Secondary | Change in tumour necrosis factor α | baseline and 14 weeks | Tumour necrosis factor α (TNFα) will be measured by quantitative sandwich enzyme immunoassays (R \& D Systems Inc, USA). |
| Secondary | Change in macrophage migration inhibitory factor | baseline and 14 weeks | Macrophage migration inhibitory factor will be measured by quantitative sandwich enzyme immunoassays (R \& D Systems Inc, USA). |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02917928
GET https://conductscience.org/api/trials/v1/NCT02917928/registered